Abstract: Various adhesive compositions are described which may optionally comprise one or more active agents such as pharmaceutical agents. The incorporation of one or more absorbents in combination with one or more crystallization inhibitors improves adhesive characteristics of the compositions. Also described are related methods of improving adhesive characteristics of adhesive compositions with the use of a combination of absorbent and inhibitor. Also described are related methods of using the compositions and articles incorporating such compositions.

Abstract: The invention relates to a chewing gum comprising at least a gum core comprising nicotine polacrilex, at least a one outer coating covering the core, comprising at least one sugar alcohol or mixtures of sugar alcohols and, at least a one portion fused onto the outer coating, wherein the portion comprises nicotine bitartrate or nicotine ditartrate dihydrate and at least one sugar alcohol or a mixture of sugar alcohols and at least one buffer present in the coating and/or in a portion fused to the coating.

Abstract: Described herein is a new process for the preparation of polysuccinimide derivatives-based core-shell microcapsules. Also described are microcapsules, as well as perfuming compositions and consumer products including these microcapsules, in particular perfumed consumer products in the form of home care or personal care products.

Abstract: An object is to provide a foamable aerosol composition that can be continuously ejected from the container to form dense and uniform foam, and that the formed foam has certain elasticity as well as can be easily spread on an object, and the foamable aerosol composition comprises a stock solution including cellulose nanofibers and a propellant is provided.

Abstract: Disclosed is a composition comprising at least one core-shell microcapsule in a suspending medium. The microcapsule comprises a core and a shell around said core. The shell comprises a hyperbranched polysaccharide selected from the group consisting of amylopectins, dextrins, hyperbranched starches, glycogen and phytoglycogen and mixtures thereof.

Abstract: Oral formulations comprising at least one cannabinoid and at least one mouthfeel experience enhancer are described. For example, methods and materials for preparing a dissolvable lozenge comprising a combination of THC and CBD and Szechuan peppercorn or an extract thereof are provided.

Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are oxidazole derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Abstract: Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor nilotinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer. In particular, the present disclosure provides a pharmaceutical composition in the form of an orally disintegrating tablet. In some embodiments, the pharmaceutical compositions can be administered without regard to food consumption. In other embodiments, the pharmaceutical compositions can be administered at a significantly lower dose as compared to a commercially available immediate-release nilotinib formulation, while providing a comparable therapeutic effect.

Abstract: An abuse deterrent pharmaceutical composition including a drug susceptible to abuse, a first acid soluble ingredient, a first buffering ingredient, and a delayed release buffering component.

Abstract: The present disclosure generally relates to pharmaceutical mouth rinse compositions comprising Neem oil that are useful for treating viral infections, including coronavirus infections.

Abstract: Aspects of the invention include extended transdermal delivery devices for delivering buprenorphine to a subject for an extended period of time, where the transdermal delivery devices include buprenorphine, an ?-hydroxy acid and a pressure sensitive adhesive. In certain instances, buprenorphine, ?-hydroxy acid and the pressure sensitive adhesive are provided as a single matrix layer formulation. Also provided are methods of using the subject extended transdermal delivery devices, as well as kits containing the extended transdermal delivery device.

Abstract: Present disclosure relates to a solvent-free method of encapsulating a hydrophobic active in personal care, hydrophobic active in crop protection or a hydrophobic active pharmaceutical ingredient (API) in polymeric nanoparticles. The method includes mixing the hydrophobic active in a polymer melt, wherein the polymer melt comprises a melt of a block co-polymer, wherein the polymer melt acts as a solvent for the hydrophobic active. The method further includes maintaining the polymer melt in water for sufficient time to allow self-assembly of the block co-polymer to encapsulate the hydrophobic active therein.

Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.

Abstract: The invention pertains to dispersible tablets comprising as active ingredient N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, methanesulfonate salt, processes for preparing the same, and processes for using the same.

Abstract: Provided are platinum(IV) compounds of Formula I or pharmaceutically acceptable salts thereof. Also provided are compositions including such compounds as well as methods of using the same.

Abstract: The present invention relates to a wound dressing material comprising a fibrillated acellular dermis matrix and a biodegradable polymer aqueous solution and, more specifically, to: a wound dressing material comprising 5-20 wt % of a fibrillated acellular dermis matrix, 0.5-5 wt % of a biodegradable polymer, and 75-94.5 wt % of water; and a preparation method therefor.

Abstract: The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.

Abstract: The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.

Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.

Abstract: This disclosure provides, among other things, compositions comprising quantities of oltipraz crystals, as well as method of making such compositions, and method of treating patients using such compositions.